Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 8:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 48 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Withdrawn Phase 1Phase 2 Interventional

Post Operative Delirium Study

NCT04635774
Conditions
Delirium
Interventions
Insulin, Saline
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Conditions
Parkinson Disease
Interventions
INS-GSH, Matched Placebos
Drug
Lead sponsor
Gateway Institute for Brain Research
Industry
Eligibility
30 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Davie, Florida • Hialeah, Florida • Miami, Florida + 1 more
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322
Conditions
Type 2 Diabetes Mellitus
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Florian Schmitzberger
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

NCT03608163
Conditions
Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemia Unawareness
Interventions
Naloxone, Diazoxide, Placebo (for Naloxone), Placebo (for Diazoxide)
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 55 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Saline, Insulin detemir, Insulin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Tacoma, Washington
Conditions
Alzheimer Disease
Interventions
Empagliflozin, Insulin, Insulin Placebo, Empagliflozin Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Schizophrenia
Interventions
Insulin or Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Parkinson Disease, Multiple System Atrophy
Interventions
Intranasal Insulin
Drug
Lead sponsor
Peter Novak
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Worcester, Massachusetts
Conditions
Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
Interventions
Carbon dioxide breathing, Neurovascular Coupling, Human insulin
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF Multi-Device Study 2

NCT04199767
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Autism Spectrum Disorder High-Functioning, Autism Spectrum Disorder With Absence of Functional Language, Autism Spectrum Disorder With Impaired Functional Language, Autistic Disorder of Childhood Onset With Full Syndrome, Autistic Disorders Spectrum, Autistic Disorder, Autistic Disorder in Children and Adolescents, Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD), Neurodevelopmental Disorders and Developmental Abnormalities
Interventions
Not listed
Lead sponsor
Healing Hope International
Other
Eligibility
4 Years to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Spring, Texas
Conditions
Healthy
Interventions
Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
36 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Chronic Multisymptom Illness in Gulf War Veterans
Interventions
Intranasal Insulin, Placebos
Drug
Lead sponsor
Bronx Veterans Medical Research Foundation, Inc
Other
Eligibility
40 Years to 89 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Insulin aspart, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
50 Years to 89 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Conditions
Type 2 Diabetes
Interventions
Placebo for Nasulin, Nasulin
Other · Drug
Lead sponsor
CPEX Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Nasal Insulin to Fight Forgetfulness - Device Study

NCT03857321
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
Insulin, Placebo, intranasal nebulizer-like device
Drug · Other · Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Out-Of-Hospital Cardiac Arrest, Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Robert Silbergleit
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Diabetes Mellitus
Interventions
Insulin (recombinant human insulin), NovoLog
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas